AtriCure Inc

AtriCure, Inc. (NASDAQ: ATRC) provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Recent Business and Financial Updates

• Impressive Revenue Growth in Q1 2024: ATRC reported revenue of USD 108.9 million for the first quarter of 2024, marking a substantial 16.4% increase compared to the first quarter of 2023 (16.3% on a constant currency basis). This growth is driven by the continued global adoption of ATRC's products by physicians. Sequentially, worldwide revenue grew by approximately 2.2% from the fourth quarter of 2023, demonstrating consistent market demand and the effectiveness of ATRC's strategic initiatives.
• Strong Performance in the U.S. Market: ATRC's U.S. revenue for the first quarter of 2024 was USD 90.2 million, a notable increase of USD 12.1 million or 15.4% compared to the same period in 2023. This impressive growth was fueled by robust sales across key product lines, including Hybrid AF™ Therapy procedures using the EPi-Sense System, the ENCOMPASS® clamp in open ablation, the AtriClip® Flex·V® device in appendage management, and the cryoSPHERE® probe for post-operative pain management. Despite the positive overall growth, the U.S. market faced some pressure from a decline in sales of the LARIAT® system in minimally invasive appendage management.
• Robust International Revenue Expansion: ATRC's international revenue experienced significant growth, increasing by USD 3.3 million or 21.5% (21.1% on a constant currency basis) to USD 18.6 million in the first quarter of 2024. This growth was evident across all franchises and geographic regions, highlighting the strong global demand for ATRC's products and the success of the company's international expansion strategies. The broad-based growth underscores ATRC's ability to penetrate diverse markets and cater to the needs of physicians worldwide.
• Enhanced Gross Profit and Margins: For the first quarter of 2024, ATRC's gross profit stood at USD 81.3 million, up from USD 69.6 million in the same period in 2023. The gross margin improved to 74.7%, a gain of 21 basis points year-over-year. This improvement reflects a more favorable product and geographic mix, showcasing ATRC's operational efficiency and strategic focus on high-margin products and markets.
• Financial Performance and Outlook: The loss from operations for ATRC in the first quarter of 2024 was USD 10.9 million, compared to USD 5.8 million for the same period in 2023, largely due to a USD 4.0 million gain from a legal settlement in 2023. Basic and diluted net loss per share was USD 0.28 for Q1 2024, compared to USD 0.14 for Q1 2023. Adjusted EBITDA for Q1 2024 was USD 2.8 million, an increase of USD 0.9 million from Q1 2023. Adjusted loss per share was USD 0.25 for Q1 2024, compared to USD 0.23 for Q1 2023. For the full year of 2024, ATRC projects revenue to be in the range of USD 459 million to USD 466 million, reflecting growth of approximately 15% to 17% over 2023. Full-year 2024 Adjusted EBITDA is expected to be between USD 26 million and USD 29 million, indicating an increase of approximately 34% to 49% over 2023. Adjusted loss per share for 2024 is anticipated to be between USD 0.74 and USD 0.82, with improvements expected annually thereafter.

Technical Observation (on the daily chart):

The Relative Strength Index (RSI) over a 14-day period stands at a value of 52.0, currently upward trending, with expectations of a consolidation or an upward consolidation zone break. Additionally, the stock's current positioning is between both the 50-period SMA and 200-period SMA, which may serve as dynamic short to medium-term support and resistance levels respectively.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘WATCH’ rating has been given to AtriCure, Inc. (NASDAQ: ATRC) at the current market price of USD 22.77 as of July 01, 2024 at 07:12 AM PT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is July 01, 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.